Replies to post #154739 on Biotech Values

[oc631]

Yes, it's in Phase 1 now with data due in mid-2013 I believe. I'm sure they will need these results, at a minimum, before they have a chance to partner.

It's somewhat surprising the stock doubled on that animal data because it's meaningless without demonstrating stellar safety in humans first. It's a long shot but you have a pretty strong batting average. Let me know when or if you buy in.

[oc631]

Yes, it's in Phase 1 now with data due in mid-2013 I believe.

ARWR is enrolling patients with castrate-resistant prostate cancer for this phase 1 obesity study. The whole thing seems rather strange. I would expect the drug to be tested first in obese patients without co-morbidities to get a clean read on the drugs safety profile. One of the primary outcome measures is disease progression. Talk about killing two birds with one stone.


ARWR's PR states

Fat tissue is known to produce substances that can promote prostate cancer growth

This is a cancer trial mislabeled as an obesity trial. Talk of follow-on formulations, and the design of this study, appears to suggest this drug won't be used within the general population nor partnered for the obesity indication.